Inflacam (20 - 25 kg)
Active substance
ATC code
Species
Dogs.
Indications
Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs.
Dose to be administered and administration route
Oral use.
Initial treatment is a single dose of 0.2 mg meloxicam/kg body weight on the first day.
Treatment is to be continued once daily by oral administration (at 24-hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg body weight.
Each chewable tablet contains either 1 mg or 2.5 mg meloxicam, which corresponds to the daily maintenance dose for a 10 kg body weight dog, or a 25 kg body weight dog respectively. Each chewable tablet can be halved for accurate dosing according to the individual body weight of the dog.
To ensure a correct dosage, body weight should be determined as accurately as possible.
The use of suitably calibrated measuring equipment is recommended.
The veterinary medicinal products can be administered with or without food, are flavoured and are taken by most dogs voluntarily.
Dose scheme for the maintenance dose:
|
Body weight (kg) |
Number of chewable tablets |
mg/kg |
|
|
1 mg |
2.5 mg |
||
|
4–7 |
½ |
0.13–0.1 |
|
|
7.1–10 |
1 |
0.14–0.1 |
|
|
10.1–15 |
1½ |
0.15–0.1 |
|
|
15.1–20 |
2 |
0.13–0.1 |
|
|
20.1–25 |
1 |
0.12–0.1 |
|
|
25.1–35 |
1½ |
0.15–0.1 |
|
|
35.1–50 |
2 |
0.14–0.1 |
|
The use of Inflacam oral suspension for dogs may be considered for an even more precise dosing. For dogs weighing less than 4 kg, the use of Inflacam oral suspension for dogs is recommended.
A clinical response is normally seen within 3–4 days. Treatment should be discontinued after 10 days if no clinical improvement is apparent.
Adverse reactions
Dogs:
|
Very rare (<1 animal / 10,000 animals treated, including isolated reports): |
Appetite loss, Lethargy Vomiting, Diarrhoea, Blood in faeces1, Haemorrhagic diarrhoea, Haematemesis, Gastric ulcer, Small intestine ulcer, Large intestine ulcer Elevated liver enzymes Renal failure |
1occult
These side effects occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal. If adverse reactions occur, treatment should be discontinued and the advice of a veterinarian should be sought.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See also the package leaflet for respective contact details.
Dispensing
POM-V - Prescription Only Medicine – Veterinarian
TRUSTED SOURCE
Similar products
Showing 2 of 2 results
Inflacam (20 - 25 kg)
